Research Project

Project Title:

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) (DUPLEX)

Project Type:

Clinical Trial, Enrolment ongoing
Adjunct biobank: DNA, Serum, Plasma, Urine

Disease group(s):

Immune glomerulopathies

Project Summary:

To determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary and genetic focal segmental glomerulosclerosis (FSGS).

Lead principal investigator(s):

Giovanni Montini, Milano
Bertrand Knebelmann, Paris

Co-investigator(s):

Myriam Dao, Paris

Project Period:

03/2018   -   12/2022

Sponsors:

Industry

ClinicalTrials.gov:

NCT03493685

EudraCT Nr.:

2016-005141-23

« Back to research page